US

Neumentum snags $6 mln Series A

Palo Alto, California-based Neumentum, a developer of non-opioid pain products, has raised $6 million in Series A funding. The backers were not named. Brookline Capital Markets was the placement agent.

NEA recruits Koplow-McAdams as venture partner

New Enterprise Associates has named Hilarie Koplow-McAdams as venture partner. Previously, Koplow-McAdams was the president at New Relic.

Maxwell Financial Labs grabs $3 mln

Denver-based Maxwell Financial Labs Inc, a provider of B2B digital mortgage cloud software, has secured $3 million in funding. Anthemis Group led the round with participation from other investors that included Route66 Ventures and Assurant Inc.

Viola amasses $100 mln for fintech fund

Israel-based tech investor Viola has raised $100 million for its new global fintech fund. The target is $120 million to $150 million. The fund's backers include Scotiabank, The Travelers Companies Inc and Bank Hapoalim.

Online luxury retailer Moda Operandi nabs $165 mln

Moda Operandi, an online luxury retailer, has closed $165 million in funding. Adrian Cheng and Apax Digital led the round with participation from other investors that included New Enterprise Associates, LVMH and Fidelity.

Anzu Partners raises $128.4 mln for maiden fund

Anzu Partners has closed its inaugural fund at $128.4 million. Anzu Industrial Capital Partners LP will invest in American and Canadian private industrial technology companies. The fund's limited partners include institutions, family offices and individuals in the U.S. and overseas.

VC-backed data platform Iguazio launches APAC regional headquarters in Singapore

Israel-based Iguazio, a data platform, has opened its Asia Pacific regional headquarters in Singapore. Iguazio's backers include Verizon Ventures, Robert Bosch Venture Capital GmbH, the Chicago Mercantile Exchange Group and Dell Technologies Capital.

AmorChem collects $44.2 mln for second fund

Montreal-based AmorChem, a life sciences venture firm, has raised $44.2 million for its second fund. AmorChem II will focus on backing "promising" life science projects originating from Québec-based universities and research centers. The fund's limited partners include the Québec government, Fonds de solidarité FTQ and Merck.

Obsidian Therapeutics scores $49.5 mln Series A

Cambridge, Massachusetts-based Obsidian Therapeutics Inc, a biotechnology company, has closed $49.5 million in Series A financing. GV led the round with participation from Atlas Venture, Takeda Ventures Inc, Vertex Ventures HC, Amgen Ventures, Alexandria Venture Investments and ShangPharma Investment Group. In addition to the funding, Obsidian has named Dr. Michael Gilman as CEO.

HealthiPass gathers $7.2 mln Series A

HealthiPass, a patient-centric digital payments platform, has raised $7.2 million in Series A funding. FCA Venture Partners led the round with participation from other investors that included OCA Ventures, Healthy Ventures, HealthX Ventures and Waterline Ventures.